Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xianshen decoction is a Traditional Chinese Medicine (TCM) herbal formulation developed by The First Affiliated Hospital of Guangzhou University of Chinese Medicine. It is primarily utilized as a supportive therapy to prevent and treat radiation-induced oral mucositis (RIOM) in patients with nasopharyngeal carcinoma undergoing radiotherapy. The decoction is a multi-herb formula typically containing ingredients such as *Radix Scrophulariae* (Xuan Shen) and *Radix Pseudostellariae* (Taizi Shen), which are traditionally used to nourish 'Yin,' clear heat, and detoxify. Its therapeutic effect is attributed to its ability to modulate the inflammatory microenvironment by downregulating the expression of pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), and by reducing oxidative stress in the oral mucosal tissues.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xianshen decoction.